CLINICAL_TRIALS
trial_result
· 2017-11-22
Clinical Trial Update: Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer [Phase 2]
Summary
Phase 2 trial update of intravenous Volasertib (BI-6727) in second-line urothelial cancer; results have been posted following study completion.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2017-11-22